Hantavirus Cardiopulmonary Syndrome Clinical Presentation
- Author: Juliet D Caldwell, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD more...
The clinical course of Hantavirus cardiopulmonary syndrome (HCPS) advances through several sequential stages.
Following exposure, an incubation period of about 3 weeks ensues. The aerosolized virus enters the lung, is taken up by local phagocytes, and is transported to local lymph nodes where it prepares to disseminate. The prodrome/febrile phase lasts 3-10 days and is marked by the onset of fever, chills, and myalgias, often severe, and is the likely clinical correlate to viral dissemination. It is nearly impossible to distinguish HCPS from any other nonspecific viral syndrome during this period. Disease severity progresses quickly, and patients often develop nausea, vomiting, weakness, and sometimes diarrhea and headache. Andes virus HCPS of South America differs slightly, presenting with facial flushing, fine petechiae, and conjunctivitis. Though rhinorrhea, pharyngitis, otalgia, and coryza are notably absent in most Hantavirus infections, a dry cough is common and often heralds sudden deterioration and progression to the cardiopulmonary phase of disease.
The cardiopulmonary phase lasts anywhere from 2-7 days and presents with sudden respiratory distress and, often, cardiovascular collapse within hours of arrival to the hospital. This phase of the illness correlates with massive capillary leakage into the pulmonary vascular bed. Immune response always precedes the abrupt deterioration into the cardiovascular phase of disease supporting the hypothesis of an immune-mediated pathogenesis. Clinical deterioration is precipitous and results in pulmonary edema, bronchorrhea, shock, and sometimes coagulopathy (Andes virus) and preterminal arrhythmias. Mean time from onset of first symptom to cardiopulmonary failure is 5 days. See the image below.
Among survivors, recovery is nearly as rapid as decline and is often accompanied by a period of diuresis. During the convalescent period, the patient typically recovers with little or no residual deficits. Several months of fatigue and decreased exercise tolerance are often the only sequelae.
Early diagnosis is difficult because the common presenting symptoms of HCPS overlap with those of other, less ominous, viral illnesses. Risk factors for rodent exposure must be sought and are often the only gateway to an early diagnosis.
Consider diagnosis of HCPS in patients with the following:
Severe myalgias (often in the back and legs)
Exposure to mice or mouse droppings
Other symptoms may include the following:
GI symptoms such as nausea and vomiting, diarrhea, and abdominal pain
Risk factors to seek in the history include the following:
Peridomestic rodent infestation
Entering or disturbing seasonally closed or infrequently opened buildings
Occupational exposure to rodents
Risk also varies with rodent abundance and distribution, which, in turn, depends on several factors, including the following:
Geographic region (highest incidence in the Southwest United States)
Seasonality (increased incidence in spring and summer)
Weather patterns (Outbreaks may follow El Nino conditions of a temperate wet winter.)
The most common prodromal symptoms are the following:
Myalgias (often in the back and legs)
Other common prodromal symptoms include the following:
Cough (usually nonproductive)
Dyspnea (usually not observed at presentation but often heralds the cardiopulmonary phase of HCPS)
Consider another diagnosis with the following symptoms:
Conjunctivitis/coryza (except Andes virus)
Rash (except Andes virus where petechiae are common)
Physical findings vary substantially with the stage of disease at presentation.
The most frequent initial physical findings in Hantavirus cardiopulmonary syndrome (HCPS) are as follows:
Crackles or decreased breath sounds are noted in most patients on lung examination.
Abdominal tenderness is present in about 10% of patients and may be severe. One patient underwent an exploratory laparotomy before HCPS was recognized.
Petechiae are not observed despite thrombocytopenia (except Andes virus).
Hallmarks of the cardiopulmonary phase of HCPS include the following:
Respiratory distress with bilateral alveolar infiltrates on radiograph
In the United States, Hantavirus cardiopulmonary syndrome (HCPS) is primarily caused by the Sin Nombre virus (SNV) and is transmitted via inhalation of aerosolized virus from dried rodent excreta (see Background and Pathophysiology).
The vector of SNV is the deer mouse, P maniculatus (see image below). SNV causes no obvious harm to mice, and they therefore never develop immunity. Infected rodents thereby become chronic, persistent viral shedders.
The incidence of HCPS closely parallels the distribution and number of infected deer mice in a geographic area. Deer mouse populations are influenced by specific environmental conditions.
The El Nino conditions present during the 1993 Navajo outbreak increased the number of deer mice seen that year. The wet and mild conditions encouraged an unusually high population of pinons, a favorite source of food for mice. This, in turn, allowed for a 10-fold increase in the number of deer mice found that year in the Four Corners region of the United States.
Because of horizontal viral transmission via intra-rodent aggressive behaviors such as biting, high rodent density also increases the percentage of deer mice infected. Thirty percent of deer mice in the Four Corners region tested positive for SNV in the 1993 outbreak.
All agree that some type of rodent exposure, whether occupational or sporadic, is the greatest risk factor for contracting Hantavirus. Some controversy exists as to whether occupational exposure on farms or in laboratories is as great a risk factor as sporadically entering rarely opened or seasonally closed rodent-infested buildings.[10, 31, 11]
Occupations at greatest risk for exposure are as follows:
Sheedy JA, Froeb HF, Batson HA, et al. The clinical course of epidemic hemorrhagic fever. Am J Med. 1954 May. 16(5):619-28. [Medline].
Lee HW, Baek LJ, Johnson KM. Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats. J Infect Dis. 1982 Nov. 146(5):638-44. [Medline].
Brummer-Korvenkontio M, Vaheri A, Hovi T, et al. Nephropathia epidemica: detection of antigen in bank voles and serologic diagnosis of human infection. J Infect Dis. 1980 Feb. 141(2):131-4. [Medline].
Avsic-Zupanc T, Xiao SY, Stojanovic R, Gligic A, van der Groen G, LeDuc JW. Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia. J Med Virol. 1992 Oct. 38(2):132-7. [Medline].
Tsai TF, Bauer SP, Sasso DR, et al. Serological and virological evidence of a Hantaan virus-related enzootic in the United States. J Infect Dis. 1985 Jul. 152(1):126-36. [Medline].
Glass GE, Watson AJ, LeDuc JW, Childs JE. Domestic cases of hemorrhagic fever with renal syndrome in the United States. Nephron. 1994. 68(1):48-51. [Medline].
Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. Infectious diseases update: outbreak, hantavirus infection--southwestern United States, 1993. JAMA. 1993 Jul 7. 270(1):25. [Medline].
Centers for Disease Control and Prevention. All About Hantavirus Web site. Available at http://www.cdc.gov/ncidod/diseases/hanta/hps.
Klein SL, Calisher CH. Emergence and persistence of hantaviruses. Curr Top Microbiol Immunol. 2007. 315:217-52. [Medline].
Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis. 2000 May. 181(5):1569-73. [Medline].
Trencseni T, Keleti B. Clinical aspects and epidemiology of haemorrhagic fever with renal syndrome. Budapest. Akademai Kiado. 1971.
Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis. 2007 Jun 1. 195(11):1563-71. [Medline].
Terajima M, Hendershot JD 3rd, Kariwa H, et al. High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis. 1999 Dec. 180(6):2030-4. [Medline].
Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis. 2006 Nov 15. 194(10):1403-9. [Medline].
Mertz GJ, Hjelle BL, Bryan RT. Hantavirus infection. Adv Intern Med. 1997. 42:369-421. [Medline].
Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004. 17(4):481-97. [Medline].
Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999. 50:531-45. [Medline].
Li Y, Wang W, Wang JP, Pan L, Zhang Y, Yu HT. Elevated vascular endothelial growth factor levels induce hyperpermeability of endothelial cells in hantavirus infection. J Int Med Res. 2012. 40(5):1812-21. [Medline].
Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol. 1995 Jan. 26(1):110-20. [Medline].
Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996 Feb. 24(2):252-8. [Medline].
Entwisle G, Hale E. Hemodynamic alterations in hemorrhagic fever. Circulation. 1957 Mar. 15(3):414-25. [Medline].
Centers for Disease Control and Prevention. Outbreak of Hantavirus Infection in Yosemite National Park. Available at http://www.cdc.gov/hantavirus/outbreaks/yosemite-national-park-2012.html. Accessed: April 17, 2013.
Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. [Epidemic outbreak of Hantavirus pulmonary syndrome in Argentina. Molecular evidence of person to person transmission of Andes virus]. Medicina (B Aires). 1998. 58 Suppl 1:27-36. [Medline].
Young JC, Hansen GR, Graves TK, et al. The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg. 2000 Jun. 62(6):714-7. [Medline].
Johnson AM, Bowen MD, Ksiazek TG, et al. Laguna Negra virus associated with HPS in western Paraguay and Bolivia. Virology. 1997 Nov 10. 238(1):115-27. [Medline].
Chang B, Crowley M, Campen M, Koster F. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med. 2007 Apr. 28(2):193-200. [Medline].
Centers for Disease Control and Prevention. Reported Cases of HPS. Available at http://www.cdc.gov/hantavirus/surveillance/index.html. Accessed: April 17, 2013.
MMWR Hantavirus Pulmonary Syndrome in Five Pediatric Patients --- Four States, 2009. December 25th 2009. 58 (50):1409-1412.
Castillo C, Naranjo J, Sepulveda A, Ossa G, Levy H. Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. Chest. 2001 Aug. 120(2):548-54. [Medline].
Koster F, Foucar K, Hjelle B, Scott A, Chong YY, Larson R. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am J Clin Pathol. 2001 Nov. 116(5):665-72. [Medline].
Jenison S, Hjelle B, Simpson S, Hallin G, Feddersen R, Koster F. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect. 1995 Dec. 10(4):259-269. [Medline].
Hjelle B. Hantavirus Cardiopulmonary Syndrome. UpToDate. 2008.
Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med. 1994 Apr 7. 330(14):949-55. [Medline].
Ketai LH, Williamson MR, Telepak RJ, et al. Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology. 1994 Jun. 191(3):665-8. [Medline].
Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg. 2008 Mar. 135(3):579-84. [Medline].
Dull SM, Brillman JC, Simpson SQ, Sklar DP. Hantavirus pulmonary syndrome: recognition and emergency department management. Ann Emerg Med. 1994 Sep. 24(3):530-6. [Medline].
Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med. 1994 Jun. 149(6):1710-3. [Medline].
Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med. 1998 Feb. 26(2):409-14. [Medline].
Hjelle B, Jenison S, Mertz G, et al. Emergency of hantaviral disease in southwestern United States. West J Med. 1994. 161:467.
Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991 Dec. 164(6):1119-27. [Medline].
Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 1999. 4(4):211-9. [Medline].
Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004 Nov 1. 39(9):1307-13. [Medline].
Vial PA, Valdivieso F, Ferres M, Riquelme R, Rioseco ML, Calvo M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013 Oct. 57(7):943-51. [Medline]. [Full Text].
Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000 Jul. 182(1):43-8. [Medline].
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr. 78(1):162-9. [Medline].
Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003 Sep. 77(18):9894-905. [Medline].
Hooper JW, Custer DM, Smith J, Wahl-Jensen V. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology. 2006 Mar 30. 347(1):208-16. [Medline].
Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol. 1990 Jul. 64(7):3162-70. [Medline].
Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg. 1992 Oct. 47(4):397-404. [Medline].
Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV. Antivir Ther. 2014 Oct 15. [Medline].
Howard MJ, Doyle TJ, Koster FT, et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis. 1999 Dec. 29(6):1538-44. [Medline].
CDC. Hantavirus pulmonary syndrome in five pediatric patients - four states, 2009. MMWR Morb Mortal Wkly Rep. 2009 Dec 25. 58(50):1409-12. [Medline].
Pergam SA, Schmidt DW, Nofchissey RA, et al. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg. 2009 Feb. 80(2):279-85. [Medline].